Biotech-stock investing has one tough test for success - and it's about to get easier ...

Wilson celebrates the first U.S. patient to complete gene therapy for sickle cell, but says advocacy must continue.

That's because FDA flexibility can mean approval for drugs that are too dangerous or simply do not work. Skorney cited a drug called Oxbryta from Pfizer (PFE), which was approved to treat the blood ...

High-yield dividend stocks have been gaining momentum ahead of potential Fed rate cuts. While sticky inflation and possible ...

Oct. 31, 2024 — A research team has found that giving iron supplements to children living with human immunodeficiency virus (HIV) in sub-Saharan Africa could be an ... Kidney Transplantation ...

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated ...

Patient enrollment and site activation progressing in Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Ended the third quarter of 2024 with $257.2 million in cash, cash equivalents ...

Meet the small band of dinosaur experts pushing palaeontology forward in Hong Kong The local discovery of dinosaur fossils in Hong Kong thrust Michael Pittman into the spotlight but few are aware ...

Global Blood Therapeutics' run of positive regulatory news for its oral sickle cell disease treatment Oxbryta has continued with an approval for the drug in Europe for patients aged over 12. The ...

The patient died four months after BEAM-101 infusion “due to respiratory failure that was determined by the investigator to ...

Sickle cell patient files lawsuit against Global Blood Therapeutics, a wholly owned subsidiary of Pfizer, alleging harm from medication. The lawsuit, filed on Hardiman's behalf by the law firm ...